ALTANA Has Withdrawn the EU Marketing Authorisation Application for Daxas
ALTANA announced that it has withdrawn the European Marketing Authorisation Application (MAA) for Daxas® (roflumilast).
ALTANA Pharma has taken this decision after consulting with the EMEA today. The submission of a new MAA will be pursued, after further clinical data are available.
ALTANA Pharma is committed to continue the development of Daxas® and will pursue further clinical studies to strengthen the anti-inflammatory product profile and possible market potential of Daxas®.
The phosphodiesterase4 (PDE4)-inhibitor Daxas® (roflumilast) is an oral investigational, steroid free anti-inflammatory agent being studied for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.